Table 3 Baseline characteristics.

From: P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials

Study name

GLOBAL leaders

SMART CHOICE

STOPDAPT-2

TWILIGHT*

TICO

MASTER DAPT

Procedure

Complex PCI

Non-complex PCI

Complex PCI

Non-complex PCI

Complex PCI

Non-complex PCI

Complex PCI

Non-complex PCI

High-ischemic ACS

Non-high-ischemic ACS

Complex PCI

Non-complex PCI

Treatment

P2Y12i

DAPT

P2Y12i

DAPT

P2Y12i

DAPT

P2Y12i

DAPT

P2Y12i

DAPT

P2Y12i

DAPT

P2Y12i

DAPT

P2Y12i

DAPT

P2Y12i

DAPT

P2Y12i

DAPT

Number

2283

2287

5434

5446

260

238

1235

1260

245

264

1255

1245

2342

4777

735

738

792

791

588

608

1707

1676

Age, year

65.3 (10.3)

65.2 (10.1)

64.2 (10.3)

64.3 (10.3)

64.7 (10.5)

64 (10.9)

64.6 (10.8)

64.4 (10.6)

69.2 (9.8)

69.8 (10.3)

68 (11.1)

68.9 (10.5)

66 (10.4)

64.7 (10.3)

62.9 (10.3)

63 (10.6)

58.7 (10.8)

59.4 (10.6)

76.51 (8.17)

76.78 (8.3)

75.98 (8.88)

75.66 (8.92)

BMI, kg/m2

28 (4.4)

28.1 (4.6)

28.2 (4.6)

28.2 (4.6)

24.6 (3.3)

24.8 (2.9)

24.5 (3.4)

24.7 (3.2)

24.3 (3.1)

24.6 (3.7)

24.4 (3.6)

24.2 (3.5)

28.1 (5.3)

28.8 (5.7)

24.9 (3)

25 (3.3)

24.9 (3.2)

24.8 (3.3)

27.56 (4.61)

27.58 (4.62)

27.15 (4.7)

27.39 (4.79)

Female

21.8

20.9

24.2

24.2

26.5

22.3

27.4

26.5

19.8

20.8

21.6

24.1

21.3

25.1

23.8

22.5

18.7

17.6

18.7

29.6

31.4

31.2

Diabetes mellitus

27.5

25.1

24.7

24.6

45.8

41.6

36.6

36

45.3

50

37.8

35.5

37

36.7

56.9

56.5

0

0

34.4

33.4

32.3

34.7

Current smoking

26.9

26.5

25.4

26.4

25.8

25.2

29

24.4

22.9

20.8

27.3

20.6

20.6

22.3

N.A

N.A

N.A

N.A

8

6.4

10.8

8.7

Hypertension

74.5

73

73.5

73.4

68.1

68.5

60.3

60

75.9

76.5

73.2

73.4

71.2

73

60

60.8

40.3

42

80.4

77

75.7

78.7

Dyslipidemia

69.8

71.2

69.2

69.6

44.2

45

45.3

45.7

78

80.3

73.7

73.6

58.2

61.6

63.7

62.1

57.6

58.7

71.4

66.3

65.7

68.7

CKD (eGFR < 60)

14.1

14

13.8

13.3

6.2

5

2.3

3.3

45.3

42

39.2

40.1

18.1

16.1

39.7

44.4

0

0

22.3

20.1

16.8

20

Previous MI

20.9

21.8

23.5

24.1

3.5

3.8

4.3

4.4

18.4

17.1

12.9

12.4

28.7

28.6

4.5

4.3

3.9

2.1

21.1

23.8

18.2

17

ACS

48.6

48.6

46.4

46.2

54.6

61.3

58.9

57.6

34.3

30.3

38.3

40.4

63.6

65.4

100

100

100

100

48.1

47.3

49.5

47.4

  1. Data are expressed as mean (standard deviation) or percentage (%).
  2. ACS acute coronary syndrome, BMI body mass index, CKD chronic kidney disease, DAPT dual antiplatelet therapy, MI myocardial infarction, P2Y12i P2Y12 inhibitor, N.A. not available.
  3. *The report from the TWILIGHT did not provide the data stratified by treatment arm.
  4. †Only in the TICO trial, patients were divided into high-ischemic ACS vs. non-high-ischemic ACS. The definition of high-ischemic ACS included not only complex PCI but also diabetes mellitus and chronic kidney disease.
Back to article page